% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Yuan:300747,
author = {T. Yuan$^*$ and D. Edelmann$^*$ and V. Moreno and E.
Georgii and L. B. de Andrade E Sousa and H. Pelin and X.
Jiang and J. N. Kather and K. E. Tagscherer and W. Roth and
M. Bewerunge-Hudler$^*$ and A. Brobeil and M. Kloor and H.
Bläker and H. Brenner$^*$ and M. Hoffmeister$^*$},
title = {{I}dentification and external validation of tumor {DNA}
methylation panel for the recurrence risk stratification of
stage {II} colon cancer.},
journal = {Translational oncology},
volume = {57},
issn = {1944-7124},
address = {Ann Arbor, Mich.},
publisher = {[Verlag nicht ermittelbar]},
reportid = {DKFZ-2025-00907},
pages = {102405},
year = {2025},
note = {#EA:C070#LA:C070#},
abstract = {Tailoring surveillance and treatment strategies for stage
II colon cancer (CC) after curative surgery remains
challenging, and personalized approaches are lacking. We
aimed to identify a gene methylation panel capable of
stratifying high-risk stage II CC patients for recurrence
beyond traditional clinical variables.Genome-wide tumor
tissue DNA methylation data were analyzed from 562 stage II
CC patients who underwent surgery in Germany (DACHS study).
The cohort was divided into a training set (N = 395) and an
internal validation set (N = 131), with external validation
performed on 97 stage II CC patients from Spain. DNA
methylation markers were primarily selected using the
Elastic Net Cox model. The resulting prognostic index (PI),
a combination of clinical factors and selected methylation
markers, was compared to baseline models using clinical
variables or microsatellite instability (MSI), with
discrimination and prediction accuracy assessed through
time-dependent receiver operating characteristic curves
(AUC) and Brier scores.The final PI incorporated age, sex,
tumor stage, location, and 27 DNA methylation markers. The
PI consistently outperformed the baseline model including
age, sex, and tumor stage in time-dependent AUC across
validation cohorts (e.g., 1-year AUC and 95 $\%$ confidence
interval: internal validation set, PI: 0.66, baseline model:
0.52; external validation set, PI: 0.72, baseline model:
0.64). In internal validation, the PI also showed a
consistently improved time-dependent AUC compared with a
combination of MSI and tumor stage only. Nevertheless, the
PI did not improve the prediction accuracy of CC recurrence
compared to the baseline model.This study identified 27
tumor tissue DNA methylation biomarkers that improved the
discriminative power in classifying recurrence risk among
stage II colon cancer patients. While this methylation panel
alone lacks sufficient prediction accuracy for clinical
application, its discriminative improvement suggests
potential value as part of a multimodal risk-stratification
tool.},
keywords = {Colon cancer (Other) / DNA methylation panel (Other) /
Prognostic index (Other) / Recurrence risk (Other)},
cin = {C060 / W110 / C070 / HD01},
ddc = {610},
cid = {I:(DE-He78)C060-20160331 / I:(DE-He78)W110-20160331 /
I:(DE-He78)C070-20160331 / I:(DE-He78)HD01-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40311420},
doi = {10.1016/j.tranon.2025.102405},
url = {https://inrepo02.dkfz.de/record/300747},
}